Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Ribociclib improves progression-free survival in advanced breast cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 1661

Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US

Prof Hortobagyi speaks with ecancer at ESMO 2016 about results from the MONALEESA2 trial of ribociclib, a CDK4/6 inhibitor, in combination with letrozole.

Compared to letrozole alone, the addition of ribociclib improves progression free survival by 44% compared to placebo, which Prof Hortobagyi hails as a paradigm shift.

Read the news story or watch the interview for more.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation